Sodium fusidate in Gillain-Barre syndrome: a case report
| Autor: | Pier Luigi Meroni, Ferdinando Nicoletti, Klaus Bendtzen, Alessandra Nicoletti, S. Giuffrida, Michele Lunetta, R. Di Marco |
|---|---|
| Jazyk: | italština |
| Rok vydání: | 1998 |
| Předmět: |
medicine.medical_specialty
medicine.medical_treatment Polyradiculoneuropathy Short Report Pharmacology Drug Administration Schedule Proinflammatory cytokine Pathogenesis Interferon-gamma Internal medicine Humans Medicine Neurologic Examination Chemotherapy Dose-Response Relationship Drug Guillain-Barre syndrome Tumor Necrosis Factor-alpha business.industry Middle Aged medicine.disease Psychiatry and Mental health Dose–response relationship Endocrinology Cytokine Interleukin-2 Female Surgery Tumor necrosis factor alpha Neurology (clinical) business Fusidic Acid Immunosuppressive Agents Ex vivo |
| Zdroj: | Scopus-Elsevier Università degli studi del Molise-IRIS |
| Popis: | A patient with Guillain-Barré syndrome is reported on who responded favourably to a short course treatment with the novel immunosuppressant sodium fusidate (Fucidin), given at a daily dose of 1.5 g for one week. Along with prompt and clear cut clinical improvement, treatment with Fucidin was associated with a rapid decline in the blood concentrations of inflammatory cytokines presumably implicated in the pathogenesis of Guillain-Barré syndrome such as interleukin-2, interferon-gamma, and tumor necrosis factor-alpha. The ex vivo production of these cytokines was also markedly diminished compared with pretreatment values. Fucidin was well tolerated and no clinical or biochemical side effects were seen. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|